Kazia Annual Report 2022

9 Kazia Theraputics Limited Annual Report 2022 June 2022 Final data from the phase II study of paxalisib in glioblastoma is presented at ASCO. Preclinical data examining the combination of paxalisib with ONC201 for treatment of DIPG is presented at the ISPNO conference. The data provides powerful support for the ongoing PNOC study, which commenced recruitment in November 2021. The Alliance study of paxalisib in brain metastases moves into an expansion cohort in breast cancer brain metastases, having seen positive signals in the initial exploratory cohort. Further cohorts continue to examine brain metastases from lung cancer and other primary tumours. Paxalisib receives orphan drug designation from FDA for the treatment of AT/RT, providing additional market exclusivity, waiver of PDUFA fees, and access to grant opportunities. 2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports Our Collaborators

RkJQdWJsaXNoZXIy MjE2NDg3